Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

41. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge B, Lin K CRD summary This review concluded that it was uncertain whether (...) prostate-specific antigen-based screening reduced prostate cancer mortality. Screening was associated with false-positive results and adverse events related to subsequent evaluation and treatment. The authors' conclusions seem appropriate, although limitations in review methods mean some relevant studies could have been missed. Authors' objectives To update the 2002 and 2008 U.S. Preventive Services Task Force (USPSTF) evidence reviews on screening and treatments for prostate cancer. Searching MEDLINE and the Cochrane

DARE.2012

43. Randomised controlled trial: Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men

Randomised controlled trial: Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men Article Text Prevention Randomised controlled trial Prostate cancer screening has no effect on prostate cancer

Evidence-Based Medicine (Requires free registration)2012

44. Cohort study: Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50

Cohort study: Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50 Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50 | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our (...) cancer screening based on family history increases between age 30 and 50 Article Text Therapeutics Cohort study Cohort analysis finds that the proportion of people who meet high risk criteria for colorectal, breast or prostate cancer screening based on family history increases between age 30 and 50 Harvey J Murff Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Ziogas A , Horick NK , Kinney AY , et al . Clinically relevant changes in family history of cancer

Evidence-Based Medicine (Requires free registration)2012

45. Prostate Cancer: Screening

Prostate Cancer: Screening Final Update Summary: Prostate Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Prostate Cancer: Screening Release Date: May 2012 This topic is in the process of being updated. Please go to the section to see the latest documents available. Recommendation Summary Population Recommendation Grade Men The U.S. Preventive Services Task Force (...) (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer. ( ) Related Information for Consumers Related Information for Health Professionals Supporting Documents ( ) ( ) ( ) Clinical Summary Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice. This summary is intended for use by primary care clinicians. ( ) Current as of: May 2012 Internet Citation: Final Update Summary: Prostate Cancer

U.S. Preventive Services Task Force2012

46. Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO

Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology | |

American Society of Clinical Oncology Guidelines2012

47. Screening for prostate cancer.

Screening for prostate cancer. Clinical practice. Screening for prostate cancer. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22029754 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Nov 24;365(21):2013-9. doi: 10.1056/NEJMcp1103642. Epub 2011 Oct 26. Clinical practice. Screening for prostate cancer. 1 . 1 Department of Medicine, University of New Mexico School of Medicine, and the Medicine Service, New Mexico Veterans Affairs Health Care System, Albuquerque, USA. rhoffman@unm.edu PMID: 22029754 DOI: [Indexed for MEDLINE] Free full

NEJM2011

48. Stratifying risk - the u.s. Preventive services task force and prostate-cancer screening.

Stratifying risk - the u.s. Preventive services task force and prostate-cancer screening. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File (...) 1 selected item: 22029756 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Nov 24;365(21):1953-5. doi: 10.1056/NEJMp1112140. Epub 2011 Oct 26. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. 1 . 1 Erasmus University Medical Center, Rotterdam, The Netherlands. PMID: 22029756 DOI

NEJM2011

49. Prostate-cancer screening - what the u.s. Preventive services task force left out.

Prostate-cancer screening - what the u.s. Preventive services task force left out. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected (...) item: 22029759 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Nov 24;365(21):1949-51. doi: 10.1056/NEJMp1112191. Epub 2011 Oct 26. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out. 1 , . 1 Department of Medicine, University of South Carolina School of Medicine, Columbia, USA. PMID: 22029759

NEJM2011

51. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer Shteynshlyuger A, Andriole GL Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of screening for prostate cancer using prostate-specific antigen, compared with no screening, using the preliminary results of the European Randomized Study of Screening

NHS Economic Evaluation Database.2011

52. PSA Test to Screen for Prostate Cancer

PSA Test to Screen for Prostate Cancer PSA Test to Screen for Prostate Cancer – TheNNTTheNNT Prostate Specific Antigen (PSA) Test to Screen for Prostate Cancer 5 for unneeded biopsy In Summary, for those who got the PSA test: Benefits in NNT 100% saw no benefit 0% were helped by preventing death from any cause 0% were helped by preventing death from prostate cancer None were helped (preventing death from any cause, preventing death from prostate cancer) Harms in NNT 20% were harmed (...) with prostate CA in their lifetime and a 3% chance of dying from prostate cancer. Autopsy studies have shown that up to 2/3 of elderly men die with asymptomatic prostate cancer. It appears that if they live long enough most men will develop prostate cancer, though it will not affect their longevity. Given the high incidence of prostate cancer, there have been aggressive efforts to screen patients with the hopes of diagnosing local (non-metastatic) cancer that can be treated before it progresses. Elevated

theNNT2011

53. Population screening act: prostate cancer screening using MRI

Population screening act: prostate cancer screening using MRI Population screening act: prostate cancer screening using MRI Population screening act: prostate cancer screening using MRI Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. Population screening act: prostate cancer screening using MRI (...) . The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2011/37. 2011 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Magnetic Resonance Imaging; Mass Screening; Prostatic Neoplasms Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523 Email: info@gr.nl AccessionNumber

Health Technology Assessment (HTA) Database.2011

54. Randomised prostate cancer screening trial: 20 year follow-up.

Randomised prostate cancer screening trial: 20 year follow-up. 21454449 2011 04 01 2011 05 24 2015 02 04 1756-1833 342 2011 Mar 31 BMJ (Clinical research ed.) BMJ Randomised prostate cancer screening trial: 20 year follow-up. d1539 10.1136/bmj.d1539 bmj.d1539 To assess whether screening for prostate cancer reduces prostate cancer specific mortality. Population based randomised controlled trial. Department of Urology, Norrköping, and the South-East Region Prostate Cancer Register. All men aged (...) . On the fourth occasion (1996), only men aged 69 or under at the time of the investigation were invited. Data on tumour stage, grade, and treatment from the South East Region Prostate Cancer Register. Prostate cancer specific mortality up to 31 December 2008. In the four screenings from 1987 to 1996 attendance was 1161/1492 (78%), 957/1363 (70%), 895/1210 (74%), and 446/606 (74%), respectively. There were 85 cases (5.7%) of prostate cancer diagnosed in the screened group and 292 (3.9%) in the control group

BMJ2011 Full Text: Link to full Text with Trip Pro

55. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. 21642681 2011 06 06 2011 06 10 2016 12 03 1538-3598 305 22 2011 Jun 08 JAMA JAMA Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. 2295-303 10.1001/jama.2011.766 Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has (...) an unknown effect on mortality. To evaluate the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Randomized controlled trial of 78,216 women aged 55 to 74 years assigned to undergo either annual screening (n = 39,105) or usual care (n = 39,111) at 10 screening centers across the United States between November 1993 and July 2001. Intervention The intervention group was offered annual screening with CA-125 for 6 years

JAMA2011

56. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. 22031728 2011 11 02 2011 11 08 2016 12 03 1538-3598 306 17 2011 Nov 02 JAMA JAMA Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. 1865-73 10.1001/jama.2011.1591 The effect on mortality of screening for lung cancer with modern chest radiographs is unknown. To evaluate the effect on mortality (...) of screening for lung cancer using radiographs in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Randomized controlled trial that involved 154,901 participants aged 55 through 74 years, 77,445 of whom were assigned to annual screenings and 77,456 to usual care at 1 of 10 screening centers across the United States between November 1993 and July 2001. The data from a subset of eligible participants for the National Lung Screening Trial (NLST), which compared chest radiograph with

JAMA2011

57. Patient-centered discussions about prostate cancer screening: a real-world approach.

Patient-centered discussions about prostate cancer screening: a real-world approach. National guidelines recommend that primary care providers discuss the risks and benefits of prostate cancer screening with their patients but give little guidance on how to fit such a complex discussion into a busy clinic encounter. The authors propose a process-oriented approach (Ask-Tell-Ask) that promotes tailored conversations and value-based recommendations. The Ask-Tell-Ask approach includes diagnosing (...) a patient's informational needs, providing targeted education based on those needs, and making a shared decision about testing. This time-efficient model emphasizes the provider's role as an interactive guide rather than a one-way supplier of information. Although there is no way to make these discussions simple, this streamlined strategy can help patients and providers efficiently negotiate the complex and important decision of screening for prostate cancer.

Annals of Internal Medicine2010 Full Text: Link to full Text with Trip Pro

58. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial 20598634 2010 08 06 2010 09 03 2016 10 19 1474-5488 11 8 2010 Aug The Lancet. Oncology Lancet Oncol. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. 725-32 10.1016/S1470-2045(10)70146-7 Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. One strategy to decrease the risk of death from (...) -71 years) and only men with raised PSA concentrations were offered additional tests such as digital rectal examination and prostate biopsies. The primary endpoint was prostate-cancer specific mortality, analysed according to the intention-to-screen principle. The study is ongoing, with men who have not reached the upper age limit invited for PSA testing. This is the first planned report on cumulative prostate-cancer incidence and mortality calculated up to Dec 31, 2008. This study is registered

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

59. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P CRD summary This review found that screening for prostate specific antigen with or without digital rectal examination (...) increased prostate cancer diagnosis but did not reduce mortality. The authors concluded that current evidence did not support the routine use of screening. The review was well-conducted and the conclusions appear reliable. Authors' objectives To assess the benefits and harms of screening for prostate cancer. Searching The authors searched PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 2005 to July 2010 to identify trials published since a Cochrane review

DARE.2010

60. Prostate Cancer Screening - BAUS Response to the UK NSC consultation on prostate cancer screening.

Prostate Cancer Screening - BAUS Response to the UK NSC consultation on prostate cancer screening. Prostate Cancer Please note that the URL for this site has changed to a 'phe.org.uk' address from 'nhs.uk'. This reflects changes we have made to hosting for this site. Translate: > Prostate Cancer The UK NSC recommendation on Prostate cancer screening/PSA testing in men over the age of 50 Recommendation Systematic population screening programme not recommended Last review completed January 2016 (...) Next review due in 2018/19 Key downloads Prostate cancer is a serious public health problem. Evidence suggests that PSA screening can reduce prostate cancer mortality by 21%. However, strategies to manage the harms of overdiagnosis and overtreatment are not yet known. Information is provided on the risks and benefits by the . Prostate cancer is a serious public health problem. Evidence suggests that PSA screening can reduce prostate cancer mortality by 21%. However, strategies to manage the harms

British Association of Urological Surgeons2010